This is a working overview of albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
In the early 1960s, Mahathir visited Japan and witnessed its remarkable recovery from the devastation of Hiroshima and Nagasaki, symbolized by the 1964 Tokyo Olympics. Mahathir announced a "Look East" policy in December 1981. Under "Look East", Mahathir particularly prioritised relations with Japan, hoping this would bolster Malaysia's economy and that Japanese work ethic, values and moral norms would have a positive influence on Malaysians. He made over 100 visits to Japan. Consistent with the "Look East" strategy adopted under his leadership, there was a major push for heavy industries by Malaysia in the early 1980s.
== Ecology == The Liliaceae are ecologically diverse. Species of Liliaceae bloom at various times from spring to late summer. The colorful flowers produce large amounts of nectar and pollen that attract insects which pollinate them (entomophily), particularly bees and wasps (hymenopterophily), butterflies (psychophily) and moths (phalaenophily). The seeds are dispersed by wind and water. Some species (e.g. Scoliopus, Erythronium and Gagea) have seeds with an aril structure that are dispersed by ants (myrmecochory). The proliferation of deer populations in many areas, due to human factors such as the elimination of their animal predators and introduction to alien environments, is placing considerable herbivory pressure on many of the family's species. Fences as high as 8 feet may be required to prevent them from consuming the plants, an impractical solution for most wild areas. Those of the genus Lilium are particularly palatable, while species in Fritillaria are repellant.
endosome Any of a class of intracellular membrane-bound organelles which serve transportation and sorting functions in eukaryotic cells as part of the endocytic cycle. They are formed when proteins or other macromolecules enter the cytoplasm inside vesicles invaginated from the cell membrane or the trans-Golgi network by endocytosis, after which they are shuttled across the cell to various destinations; e.g. endosomes carrying foreign molecules often fuse with lysosomes, where the contents are then degraded.
Sources: en.wikipedia.org
Hemoglobinopathy is the medical term for a group of inherited blood disorders involving the hemoglobin, the major protein of red blood cells. They are generally single-gene disorders and, in most cases, they are inherited as autosomal recessive traits. There are two main groups: abnormal structural hemoglobin variants caused by mutations in the hemoglobin genes, and the thalassemias, which are caused by an underproduction of otherwise normal hemoglobin molecules. The main structural hemoglobin variants are HbS, HbE and HbC. The main types of thalassemia are alpha-thalassemia and beta thalassemia.
Other researchers of the entities seemingly encountered by DMT users describe them as "entities" or "beings" in humanoid as well as animal form, with descriptions of "little people" being common (non-human gnomes, elves, imps, etc.). Strassman and others have speculated that this form of hallucination may be the cause of alien abduction and extraterrestrial encounter experiences, which may occur through endogenously-occurring DMT. Likening them to descriptions of rattling and chattering auditory phenomena described in encounters with the Hayyoth in the Book of Ezekiel, Rick Strassman notes that participants in his studies, when reporting encounters with the alleged entities, have also described loud auditory hallucinations, such as one subject reporting typically "the elves laughing or talking at high volume, chattering, twittering". Researchers such as Robin Carhart-Harris and David E. Nichols among others believe that DMT entities are merely illusions and hallucinations. However, Andrew Gallimore believes that entity encounters are real and genuine interactions with other-dimensional beings. Neurocomputational models of entity encounters have been proposed, for instance by Carhart-Harris and colleagues.
1 September Resurrecting the Mammoth, about the revival of the woolly mammoth; there may be 10 million frozen mammoths in northern Siberia, and many around the Kolyma (river); the Condover mammoth of Shropshire, found in 1986, with a model at the Shropshire Hills Discovery Centre; in 1796, the first true picture of a mammoth was drawn by French zoologist Georges Cuvier; Kazufumi Goto wanted to resurrect the mammoth; Andrei Sher of the Russian Academy of Sciences; the Beryozovka mammoth of 1901 in Beryozovka (Kolyma), is one of the best preserved mammoths found; the Kirgilyakh mammoth (Dima), found on 23 June 1977 on the Kirgilyakh Peninsula; zoologist Adrian Lister, and DNA fragments of the mammoth; Australian reproductive biologist Ceinwen Gearon; Dan Fisher; geoscientist Paul Schultz Martin, and the Quaternary extinction event in the Late Pleistocene that led to the disappearance of the Mammoth species, possibly associated with Clovis culture; geoarchaeologist Vance Haynes; Larry Agenbroad; archaeologist Steven Mithen.
Sources: en.wikipedia.org
The UK NHS in 2019 listed Humira, Amgevita, Hulio, Hyrimoz, Idacio, and Imraldi as biosimilars available on (almost free) prescription, to be updated in February 2022. The annual cost of adalimumab, the costliest NHS drug, was expected to drop from £400m to £100m by 2021, the biggest saving in NHS history from a single drug negotiation. The best-selling drugs list published by Genetic Engineering & Biotechnology News, shows that Humira occupied the #1 position for 2015 (US$14.012 billion) and 2016 (US$16.078 billion) From 2012 until the US patent expired in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had US$16 billion of global sales. AbbVie reported that Humira achieved US$18.427 billion of sales in 2017. Humira had the largest worldwide drug sales in 2019 and 2020 of US$19.7bn and US$20.4bn respectively.
=== Non-beverage uses === Instant coffee is used as a flavouring for baked goods, confections, ice creams and food such as stews. Instant coffee is one of the possible ingredients in Caffenol, a non-toxic black-and-white photographic developer using standard household items developed in 1995 by a photographic chemistry class at Rochester Institute of Technology. In crafts, instant coffee can be used to stain paper to look aged.
This gave SWAPO 41 seats in the territory's Constituent Assembly, but not a two-thirds majority which would have enabled it to unilaterally draft a constitution without the other parties represented. South West Africa formally obtained independence as the Republic of Namibia on 21 March 1990.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.